AMAG (AMAG) Shares Collapse as Board Quietly Abandons Active Sale Process
Tweet
Share
E-mailGet Alerts AMAG Hot Sheet
Join SI Premium – FREE
Shares of AMAG Pharma (Nasdaq: AMAG) are getting sold Thursday as investors are responding to news the company will shift its "focus from an active sale process to the continued growth of Feraheme and the pursuit of business development opportunities."
The development was issued in a release which disclosed the appointment of William Heiden as the company's new President and CEO. Sneaky.
Analysts at both Baird and Ladenburg Thalmann downgraded shares of AMAG amid the news.
The stock last traded at $13.87, down about 13.4 percent from Wednesday's closing price.
The development was issued in a release which disclosed the appointment of William Heiden as the company's new President and CEO. Sneaky.
Analysts at both Baird and Ladenburg Thalmann downgraded shares of AMAG amid the news.
The stock last traded at $13.87, down about 13.4 percent from Wednesday's closing price.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Solowin Holdings marks 10 years, expands into stablecoins and AI
- Home Depot expands executive roles, grants $500K in restricted stock
Create E-mail Alert Related Categories
Corporate News, Insiders' BlogRelated Entities
Robert W Baird, Ladenburg Thalmann Financial ServicesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
